Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies.
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 21, 2022 | Debt Financing | $40M | 1 | Silicon Valley Bank | — | Detail |
May 9, 2022 | Series B | $147.50M | 15 | GV LYFE Capital Revelation Partners | — | Detail |
Apr 1, 2020 | Series A | $70M | 6 | OrbiMed | — | Detail |
Dec 12, 2019 | Seed | $6.50M | 6 | Domain Associates | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Silicon Valley Bank | Yes | Debt Financing |
GV | Yes | Series B |
LYFE Capital | Yes | Series B |
Revelation Partners | Yes | Series B |
Alexandria Venture Investments | — | Series B |
ARCH Venture Partners | — | Series B |
Bioverge | — | Series B |
EDBI | — | Series B |
Frazier Life Sciences | — | Series B |
Lifeforce Capital | — | Series B |